Application Area Volassom
Used for a wide range of dermal correction procedures, Volassom offers an advanced approach to facial and body volume restoration. Formulated with calcium hydroxyapatite microspheres suspended in a biocompatible gel matrix, this product supports long-lasting sculpting without surgery. A single injection session can target deep-set wrinkles, soft tissue depressions, and age-related volume loss. Practitioners often apply Volassom filler in areas such as the chin, cheeks, jawline, and nasolabial folds, with additional success in hand rejuvenation and even acne scar revision. Its versatility across treatment zones makes it a core part of many aesthetic regimens.
Strengths of Volassom Filler
What distinguishes Volassom filler is its dual action: immediate volumizing and gradual collagen stimulation. Thanks to caha in the product technology, which features stable calcium hydroxyapatite microspheres, the product offers a firm yet natural contouring effect. The addition of lidocaine ensures patient comfort during application, while the formula’s resilience helps it resist distortion from facial muscle activity.
Key strengths include:
- Biocompatible formulation with no inflammatory response
- Natural degradation and uniform breakdown over time
- Long-lasting results (1.5–2 years depending on patient factors)
- Effective support for tissue regeneration as a biostimulator
Who is This Product For
Ideal for clients seeking durable, non-surgical volume correction, Volassom skin booster caters to both preventative and corrective cosmetic needs. It is suitable for individuals with visible signs of aging, volume loss, or skin laxity who want a biocompatible, high-performance injectable. Professionals in clinics worldwide use Volassom caha formulations to meet the rising demand for fillers that deliver structure, support, and subtle refinement in one trusted injection. Whether used for wrinkle correction or facial sculpting, the product ensures natural, clinically reliable outcomes.
There are no reviews yet.